Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8860335 | 0.84 | MEN1 (0.49) | MEN1KMT2AHPGDHSD17B10TDP1 | |
| SCHEMBL11477213 | 0.83 | MEN1 (0.50) | MEN1KMT2AHPGDHSD17B10TDP1 | |
| SCHEMBL3867305 | 0.81 | HPGD (0.60) | MEN1KMT2AHPGDHSD17B10TDP1 | |
| SCHEMBL630931 | 0.80 | MEN1 (0.64) | MEN1KMT2AHPGDHSD17B10TDP1 | |
| SCHEMBL8871621 | 0.79 | MEN1 (0.54) | MEN1KMT2AHPGDHSD17B10TDP1 | |
| SCHEMBL14740086 | 0.79 | HSD17B10 (0.54) | MEN1KMT2AHPGDHSD17B10TDP1 | |
| SCHEMBL7855409 | 0.79 | MEN1 (0.54) | MEN1KMT2AHPGDHSD17B10TDP1 | |
| SCHEMBL21591572 | 0.77 | HIF1A (0.39) | MEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL11414055 | 0.77 | MEN1 (0.51) | MEN1KMT2AHPGDHSD17B10TDP1 | |
| SCHEMBL12419714 | 0.77 | HPGD (0.64) | MEN1KMT2AHPGDHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| US-7037918-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | disclosed |
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2003-07-10 | — | — | US | disclosed |
| EP-1317433-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6489344-B1 | FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT | CHIRON CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| US-6417185-B1 | HETEROCYCLIC ENZYME INHIBITORS | CHIRON CORPORATION | 2002-07-09 | — | — | US | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| EP-0008653-B2 | N-substituted benzimidazoles, processes for their preparation and medicines containing them | C.H. BOEHRINGER SOHN (DE) | 1988-05-04 | — | — | EP | disclosed |
| US-4647563-A | ANTISPAMODIC AGENTS, MUSCLE RELAXANTS, ANTIALLERGENS HYPOTENSIVE AGENTS | BOEHRINGER INGELHEIM KG (DE) | 1987-03-03 | — | — | US | disclosed |
| US-4581367-A | BRONCHOSPASMOLYTICS, ANTIALLERGENS, HYPOTENSIVE AGENTS | BOEHRINGER INGELHEIM KG (DE) | 1986-04-08 | — | — | US | disclosed |
| US-4378361-A | BRONCHODILATOR, MUSCLE RELAXANTS, ANTIALLERGENS, AND HYPOTENSIVE AGENT | BOEHRINGER INGELHEIM KG (DE) | 1983-03-29 | — | — | US | disclosed |
| EP-0008653-B1 | N-substituted benzimidazoles, processes for their preparation and medicines containing them | C.H. BOEHRINGER SOHN (DE) | 1982-06-16 | — | — | EP | disclosed |
| EP-0008653-A1 | N-substituted benzimidazoles, processes for their preparation and medicines containing them | C.H. BOEHRINGER SOHN (DE) | 1980-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | MEN1 3334/4885KMT2A 3490/4885HPGD 1619/4885 |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | MEN1 3376/4885KMT2A 3652/4885HPGD 1602/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | MEN1 3376/4885KMT2A 3652/4885HPGD 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.